Pre-course Session: Investigational Medicinal Products (IMP) QP Education Course
Im Auftrag der European QP Association

Pre-course Session: Investigational Medicinal Products (IMP) QP Education Course Im Auftrag der European QP Association

Hamburg, Germany

Seminar Nr. 18048

 

Unser Seminarservice

Kosten

Dieses Seminar/Webinar kann nicht gebucht werden. Alternative Termine für dieses Seminar/Webinar und ähnliche Veranstaltungen finden Sie in der Übersicht nach Thema..

Für viele Seminare und Webinare gibt es auch Aufzeichnungen, die Sie jederzeit bestellen und anschauen können. Diese Aufzeichnungen finden Sie in einer themensortierten Liste.

Oder senden Sie uns Ihre Anfrage einfach über das folgende Kontaktformular.

Anfrage senden
* auch unkompliziert per Kreditkarte bezahlbar American Express Visa Mastercard

Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de

Sprecher

Susanne Ding, Boehringer Ingelheim, Germany
Sue Mann, Sue Mann Consultancy, U.K.
Brenda Van Assche, Janssen, Belgium

Zielsetzung

This pre-course session provides a detailed overview of the specific characteristics in IMP manufacturing a QP must know to certify IMP batches for the release for clinical Trials.

Hintergrund


The manufacture of investigational medicinal products (IMPs), including labelling, packaging, testing and certification, is carried out in accordance with the applicable GMP regulations. However, this is not a routine process, since, among other things, manufacturing and packaging procedures might be different for each and every clinical trial. The Qualified Person (QP) must therefore take into account these particularities and the GMP/GCP interface.

Zielgruppe

New colleagues becoming IMP QPs, QPs looking for continuous training and personnel of CROs and “non-commercial” IMP organisations.

Programm

General introduction
  • Different clinical phases I to IV, focus on patient safety
  • Undefined processes (manufacture, fit for purpose control strategy, etc.)
  • Why use risk assessments & how to apply – vital core of a IMP quality system
  • Diversity: IMP manufacturers, start-ups, academia…
Specific legal requirements for IMPs
  • Clinical Trial Regulation EU No. 536/2014 and the “old” Annex 13 and Directives 2001/20/EC and 2003/94/C
  • The “new” ATMP regulation
GMP meets clinical trials – Differences between IMPs and commercial Products
  • Packaging & labeling
  • Randomization
  • Blinding / placebos
  • Comparators
  • NIMPs / AMPs
  • Where to apply validation activities
  • The Product Specification File (PSF)
  • 3rd country manufacture of IMPs: import and the QP Declaration
Registration
  • IMPD, CTA, IND etc.
  • Regulatory compliance and the two step release procedure
GMP/ GDP/ GCP Interface
  • Interaction with clinical sites
  • Distribution
  • IRT

Zurück

GMP Seminare nach Thema